GlassScriptPhysician profile
Keri Melancon
NPI 1538365424
$3,521.07
in general payments reported to CMS, 2019-2025
32 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $229 · 2021: $151 · 2022: $535 · 2023: $994 · 2024: $850 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $458.72 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $329.22 | 2022-2025 | |
| Pfizer INC. | $305.95 | 2019-2025 | |
| Abbvie INC. | $288.34 | 2022-2025 | |
| Lilly USA, LLC | $248.04 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.29 | 2019-2024 | Ofev, Jardiance |
| Dexcom, INC. | $222.88 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $177.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $175.39 | 2019-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $155.68 | 2023-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $111.14 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $96.37 | 2022-2024 | Eliquis, Camzyos |
| Boston Scientific Corporation | $86.80 | 2024-2025 | Wavewriter Alpha Prime 16, Bodyguardian |
| Amgen INC. | $83.35 | 2019-2025 | Repatha, Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $67.68 | 2022-2024 | Gvoke Hypopen |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $65.79 | 2019-2021 | |
| Amarin Pharma, INC. | $60.63 | 2020-2021 | |
| Daiichi Sankyo INC. | $42.28 | 2022-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $40.87 | 2022 | |
| Sanofi-Aventis U.S. LLC | $38.37 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $27.85 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.48 | 2025 | Voquezna |
| Corcept Therapeutics | $20.25 | 2023 | Korlym |
| Merck Sharp & Dohme LLC | $19.19 | 2024 | Gardasil, Gardasil 9 |
| Cequr Corporation | $19.04 | 2024 | Cequr Simplicity |
| Philips North America LLC | $17.02 | 2020 | |
| Tandem Diabetes Care, INC. | $16.91 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Biohaven Pharmaceuticals, INC. | $14.31 | 2021 | |
| Medtronic, INC. | $14.28 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.53 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Melancon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.